Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 17, 2026

Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance

View original at globenewswire.com
Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance 15 % Anstieg der Lizenzeinnahmen 11 % Anstieg der GesamtumsätzeNettoliquidität verdreifacht Phase-3-Programm mit Fosmanogepix verläuft wie geplantGesamtumsatz und Betriebsgewinn 2026: zweistelliges Wachstum erwart…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cumulative positive cash flows of approximately CHF 600 million are expected from Cresemba and Zevtera over the next five-year period

    80% confidence

  • Cresemba generic competition could impact US market from Q4 2027 and European market from H2 2028

    80% confidence

  • Zevtera is expected to gain increasing momentum in the USA from Q2 2026

    80% confidence

  • Potential additional non-dilutive R&D funding of approximately USD 330 million from existing BARDA contracts may be allocated in further tranches

    80% confidence

  • Royalty revenues expected to rise to approximately CHF 120 million and milestone payments to CHF ~35 million in FY2026

    80% confidence

  • FY2026 total revenue is expected to increase by approximately 10%, R&D expenses by approximately 20%, and operating profit by approximately 20%

    80% confidence

  • Basilea reduced the nominal value of outstanding convertible bonds by approximately 22% to CHF 76 million and increased cash position to CHF 162 million in 2025

    80% confidence

  • Phase-3 studies for Fosmanogepix are on track for a data readout in early 2028

    80% confidence

  • Basilea aims to have four drugs on the market by 2030 as well as a broadly positioned R&D pipeline

    80% confidence

  • Since early 2022, Basilea has reduced its financial debt by approximately CHF 145 million

    80% confidence

  • Fosmanogepix and Ceftibuten-Ledaborbactam have potential to double today's in-market revenues by 2030

    80% confidence

  • Basilea has developed into a profitable company with continuously double-digit growth in in-market revenues of products and a leading R&D pipeline in its focus area

    80% confidence

  • Cresemba and Zevtera-based revenues expected to reach approximately CHF 200 million in FY2026

    80% confidence

Cited in these Via News reports